Pharmaceuticals

Painreform

PainReform Ltd. Completes Development Assessment on LayerBio's Continuous-Release Ophthalmic Drug Delivery Platform

PainReform Announces DeepSolar's AI Report Engine, Rated Poorly by TipRanks

Painreform released FY2025 Semi-Annual earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.0906

Painreform released FY2025 Q2 earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5453

Painreform released FY2025 Q1 earnings on October 1, 2025 (EST) with actual revenue of USD 0 and EPS of USD -0.5453

PainReform Ltd. Collaborates with LayerBio for Ophthalmic Pain Treatment Clinical Trial

Blade Ranger Holds a Large Number of PainReform Warrants

PainReform and Econergy Launch Solar Plant Pilot Project in Romania

Painreform released FY2024 9 Months Earnings on April 7, 2025 (EST) with actual revenue of USD 0 and EPS of USD -116.4161

Painreform released FY2024 Q3 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6014 (forecast USD -18.96)

Painreform released FY2024 Q4 earnings on April 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.6014 (forecast USD -7.68)

Painreform released FY2024 annual earnings on April 7, 2025 (EST), with actual revenue of USD 0 and actual EPS of USD -32.1644 (forecast EPS USD -78.9599)

PainReform's Acquisition Boosts Its Competitiveness in AI Solar Management

PainReform Receives Notification from Nasdaq Regarding Minimum Shareholder Equity Requirements

PainReform Ltd Applies for Mixed Listing

Painreform released FY2024 Q2 earnings on August 15 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -22.7395 (forecast USD -24.96)

Painreform released FY2024 Semi-Annual earnings on August 15 (EST), actual revenue USD 0, actual EPS USD -63.1456

Painreform released FY2024 Q1 earnings on May 15 (EST), actual revenue 0 USD, actual EPS -65.2161 (forecast EPS -14.40)

Painreform released FY2023 annual earnings on February 29, 2024 (EST), with actual revenue of USD 0 and EPS of USD -63.1295 (forecast EPS USD -118.7999)

Painreform released FY2023 Cumulative Q3 Earnings on November 15, 2023 (EST), with Revenue at 0 and EPS at -98.2978

A SPAC III Acquisition

PicoCELA

Davis Commodities

Society Pass

ECD Automotive Design

Gauzy

Bristol-Myers Squibb Company

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS)02/01/2026

Paranovus ENT Tech

Cue BioPharma

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap